| 000 | 01187 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250516133702.0 | ||
| 264 | 0 | _c20130503 | |
| 008 | 201305s 0 0 eng d | ||
| 022 | _a1531-703X | ||
| 024 | 7 |
_a10.1097/CCO.0b013e32835de8ee _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBouabdallah, Krimo | |
| 245 | 0 | 0 |
_aTemsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. _h[electronic resource] |
| 260 |
_bCurrent opinion in oncology _cMar 2013 |
||
| 300 |
_aS1-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 |
_aSirolimus _xadministration & dosage |
| 700 | 1 | _aRibrag, Vincent | |
| 700 | 1 | _aTerriou, Louis | |
| 700 | 1 | _aSoria, Jean-Charles | |
| 700 | 1 | _aDelarue, Richard | |
| 773 | 0 |
_tCurrent opinion in oncology _gvol. 25 Suppl 2 _gp. S1-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/CCO.0b013e32835de8ee _zAvailable from publisher's website |
| 999 |
_c22484566 _d22484566 |
||